J&J's new ketamine-like depression drug Spravato off to 'very, very strong start,' company saysCNBC • 04/16/19
Johnson & Johnson's stock rises after profit and sales beat, raised sales guidanceMarket Watch • 04/16/19
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New DealZacks Investment Research • 04/12/19
Looking for a Growth Stock? 3 Reasons Why Johnson & Johnson (JNJ) is a Solid ChoiceZacks Investment Research • 04/12/19
Earnings Preview: Johnson & Johnson Q1 Earnings Expected to DeclineZacks Investment Research • 04/09/19
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug ApprovalsZacks Investment Research • 03/29/19